Breaking News

Pfizer Invests $25M in Caribou Biosciences

Funding to advance CB-011, an immune cloaked allogeneic CAR-T cell therapy currently being evaluated in a Phase 1 trial in R/R multiple myeloma.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Pfizer has made a $25 million equity investment in Caribou Biosciences, Inc., a clinical-stage CRISPR genome-editing biopharmaceutical company.    Caribou will use the investment to advance CB-011, an immune cloaked allogeneic CAR-T cell therapy currently being evaluated in the CaMMouflage Phase 1 trial in patients with relapsed or refractory multiple myeloma (r/r MM). Caribou will maintain full ownership and control of its pipeline of allogeneic CAR-T and CAR-NK cell therapies.   “We believ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters